APR Corporation Announces 2025 Q3 Earnings and Hosts Online Earnings Presentation Call

APR Corporation Announces 2025 Q3 Earnings and Hosts Online Earnings Presentation Call

SEOUL, South Korea, Nov. 3, 2025 /PRNewswire/ -- The major player of K-Beauty phenomenon, APR Corporation (APR Corp, CEO Byunghoon Kim) has announced that it will release its provisional third-quarter results for 2025 and hold an online earnings...

XPENG Announces Vehicle Delivery Results for October 2025

XPENG Announces Vehicle Delivery Results for October 2025

Sets new monthly record with 42,013 vehicles delivered in October, up 76% YoY Exceeds 40,000 monthly deliveries for the second consecutive month GUANGZHOU, China, Nov. 1, 2025 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and...

Cboe Global Markets Reports Results for Third Quarter 2025 and Announces Strategic Realignment of Business Portfolio

Cboe Global Markets Reports Results for Third Quarter 2025 and Announces Strategic Realignment of Business Portfolio

Third Quarter Highlights* Record Diluted EPS for the Quarter of $2.85, Up 38 percent Record Adjusted Diluted EPS¹ for the Quarter of $2.67, Up 20 percent Record Net Revenue for the Quarter of $605.5 million, Up 14 percent Increases 2025 Organic...

Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance

Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance

OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease DualView imaging catheter offers a 150mm maximum pullback length, a 2.6...

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022

SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of...

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for...

Save Now, Travel through March: T'way Air Announces Fall Savings to Korea

Save Now, Travel through March: T'way Air Announces Fall Savings to Korea

Promo Code FLYOCT & Special Coupons for Travel through March 2026 TAIPEI, Oct. 20, 2025 /PRNewswire/ -- T'way Air, Korea's leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for...

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily...

Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other

Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other

AMT-116 is a potential first-in-class CD44v9-directed Topoisomerase I inhibitor-based ADC AMT-116 demonstrated a favorable safety profile, with manageable hematologic and Gastrointestinal toxicities Promising efficacies were observed in patients...

The St. Regis Bar Macao Announces Collaboration with Guerlain for L'Art & La Matière Afternoon Tea

The St. Regis Bar Macao Announces Collaboration with Guerlain for L'Art & La Matière Afternoon Tea

MACAO, Oct. 16, 2025 /PRNewswire/ -- The St. Regis Bar Macao is pleased to present an exclusive collaboration with the Parisian alchemist – Guerlain, a legendary House of high perfumery and high cosmetics, from October 16 to November 15, 2025. The...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 18
  • menu
    menu